David Neu named president of AmerisourceBergen Drug Corporation
This article was originally published in Scrip
AmerisourceBergen, a pharmaceutical services companies serving the US, Canada and selected global markets, has promoted David Neu to president of AmerisourceBergen Drug Corporation (ABCD), the company's largest operating unit. Mr Neu, a 29-year veteran of the company, was most recently senior vice-president of operations for ABDC. He fills the role previously held by Steven Collis, currently executive vice-president and chief operating officer, who was recently named successor to the company's CEO, David Yost, upon his retirement on 1 July.
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.